Abstract
Objective:The aim of this systematic review and meta-analysis was to evaluate the impact of supportive pen-implant therapy (SPIT) on the rates of pen-implant diseases and pen-implant marginal bone loss. Data sources: The guidelines of PRISMA statement were followed in searching for randomized controlled trials, controlled clinical trials, and retrospective studies in several electronic databases and reference lists. The Cochrane Collaboration's Risk of Bias tools for nonrandomized studies were used to assess the risk of bias. Data were analyzed using statistical software. A total of 159 studies were identified. Five trials, with 1,570 implants in 617 patients, met the inclusion criteria. Overall meta-analysis showed significantly reduced rates of peri-implantitis with SPIT compared with non-SPIT at implant and patient levels. Pen-implant mucositis was significantly reduced with SPIT at implant level only. Pen-implant marginal bone loss was significantly reduced in patients with SPIT compared to those who did not attend SPIT. Conclusion: SPIT can significantly reduce the rate of peri-implantitis and marginal bone loss. The evidence on the role of SPIT in reducing the rate of pen-implant mucositis, on the other hand, remains limited. Further well-designed studies on the impact of SPIT on implant treatment outcome are still needed. Clinical significance: There is a need to adopt a SPIT regimen for patients receiving implant therapy to reduce the rate of peri-implant diseases and marginal bone loss. This need should be stipulated in the patient information and consent forms prior to implant therapy.